Display options
Cite
Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med. 2010;2:163-73doi: 10.2147/HMER.S7132.
Cabibbo, G., Antonucci, M., & Genco, C. (2010). Update on new approaches in the management of hepatocellular carcinoma. Hepatic medicine : evidence and research, 2163-73. https://doi.org/10.2147/HMER.S7132
Cabibbo, Giuseppe, et al. "Update on new approaches in the management of hepatocellular carcinoma." Hepatic medicine : evidence and research vol. 2 (2010): 163-73. doi: https://doi.org/10.2147/HMER.S7132
Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med. 2010 Nov 26;2:163-73. doi: 10.2147/HMER.S7132. PMID: 24367214; PMCID: PMC3846806.
Copy Download .nbib Format: NLM
Share it on

Hepat Med. 2010 Nov 26;2:163-73. doi: 10.2147/HMER.S7132.

Update on new approaches in the management of hepatocellular carcinoma.

Hepatic medicine : evidence and research

Giuseppe Cabibbo, Michela Antonucci, Chiara Genco

Affiliations

  1. Sezione di Gastroenterologia, Di.Bi.Mi.S., University of Palermo, Italy ; Dipartimento di Biopatologia e Metodologie Biomediche, University of Palermo, Italy.
  2. Department of Oncology, Division of General and Oncological Surgery, University of Palermo, Italy.
  3. Sezione di Gastroenterologia, Di.Bi.Mi.S., University of Palermo, Italy.

PMID: 24367214 PMCID: PMC3846806 DOI: 10.2147/HMER.S7132

Abstract

Hepatocellular carcinoma (HCC) is a major health problem. It is currently the third cause of cancer-related death, it is highly prevalent in the Asia-Pacific region and Africa, and is increasing in Western countries. The natural history of HCC is very heterogeneous and prediction of survival in individual patients is not satisfactory because of the wide spectrum of the disease. During the past decade, major advances have been achieved in prevention, through better surveillance of patients at risk, and in therapy through better surgical and ablative therapies and multimodal treatment approaches. Moreover, the increasing knowledge of molecular hepatocarcinogenesis provides the opportunity for targeted therapies. In this setting, the impact of sorafenib on advanced-stage HCC is a landmark finding in the treatment of liver cancer. The role of sorafenib administration as adjuvant therapy after curative treatment is being evaluated in clinical studies. Future research should lead to a molecular classification of the disease and a more personalized treatment approach.

Keywords: hepatocellular carcinoma; sorafenib

References

  1. Gut. 1998 Mar;42(3):442-7 - PubMed
  2. Ann Surg Oncol. 2008 Apr;15(4):993-1000 - PubMed
  3. Hepatology. 2010 Apr;51(4):1274-83 - PubMed
  4. Gut. 1993 Nov;34(11):1598-600 - PubMed
  5. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  6. Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 - PubMed
  7. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  8. World J Gastroenterol. 2007 Jun 21;13(23):3164-70 - PubMed
  9. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  10. Eur J Gastroenterol Hepatol. 2010 Apr;22(4):391-8 - PubMed
  11. Lancet Oncol. 2009 Aug;10(8):794-800 - PubMed
  12. Gastroenterology. 1995 Sep;109(3):917-22 - PubMed
  13. Dig Liver Dis. 2010 Oct;42(10):729-34 - PubMed
  14. Ital J Gastroenterol. 1994 Mar;26(2):66-8 - PubMed
  15. Hepatology. 1995 Sep;22(3):983-93 - PubMed
  16. Hepatology. 2002 May;35(5):1164-71 - PubMed
  17. J Clin Oncol. 2005 Sep 20;23(27):6657-63 - PubMed
  18. Hepatology. 2002 Nov;36(5):1221-6 - PubMed
  19. Semin Liver Dis. 1999;19(3):329-38 - PubMed
  20. Hepatology. 1993 Mar;17(3):389-94 - PubMed
  21. J Hepatol. 1990 Sep;11(2):181-4 - PubMed
  22. Hepatology. 2002 Sep;36(3):687-91 - PubMed
  23. J Clin Oncol. 2005 Jul 1;23(19):4338-46 - PubMed
  24. J Clin Oncol. 2005 May 1;23(13):2892-9 - PubMed
  25. Dig Dis. 2009;27(2):142-7 - PubMed
  26. Gastroenterology. 2004 Apr;126(4):1005-14 - PubMed
  27. Lancet. 1998 Jul 4;352(9121):17-20 - PubMed
  28. Cancer Treat Rev. 2011 May;37(3):212-20 - PubMed
  29. N Engl J Med. 1995 May 11;332(19):1256-61 - PubMed
  30. J Gastroenterol Hepatol. 2001 Apr;16(4):452-9 - PubMed
  31. J Clin Oncol. 2006 Apr 20;24(12):1898-903 - PubMed
  32. Cancer. 2000 May 1;88(9):1986-91 - PubMed
  33. Liver Int. 2009 Apr;29(4):502-10 - PubMed
  34. J Clin Oncol. 2008 Jun 20;26(18):2992-8 - PubMed
  35. Hepatology. 1998 Jun;27(6):1578-83 - PubMed
  36. Eur J Cancer. 2009 Jul;45(10):1788-97 - PubMed
  37. Dig Liver Dis. 2010 Jul;42 Suppl 3:S235-41 - PubMed
  38. Clin Liver Dis. 2007 Feb;11(1):191-207, x-xi - PubMed
  39. Am J Gastroenterol. 2010 Mar;105(3):599-609 - PubMed
  40. J Hepatol. 1994 Jun;20(6):702-6 - PubMed
  41. Cancer. 2007 Sep 1;110(5):1059-67 - PubMed
  42. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  43. Liver Int. 2009 Apr;29(4):478-80 - PubMed
  44. Br J Cancer. 2001 Apr 6;84(7):881-5 - PubMed
  45. Hepatology. 1995 Jun;21(6):1535-42 - PubMed
  46. Liver Int. 2010 May;30(5):741-9 - PubMed
  47. J Clin Oncol. 2009 Jun 20;27(18):3027-35 - PubMed
  48. J Clin Oncol. 2009 Feb 20;27(6):843-50 - PubMed
  49. J Clin Gastroenterol. 1998 Apr;26(3):200-3 - PubMed
  50. Lancet. 2002 May 18;359(9319):1734-9 - PubMed
  51. Gut. 2010 May;59(5):638-44 - PubMed
  52. J Clin Oncol. 1998 Feb;16(2):411-7 - PubMed
  53. Gastroenterology. 1989 Jun;96(6):1566-71 - PubMed
  54. Dig Liver Dis. 2010 Jul;42 Suppl 3:S258-63 - PubMed
  55. Aliment Pharmacol Ther. 2008 Jul;28(1):62-75 - PubMed
  56. Gastroenterology. 2002 Jul;123(1):134-40 - PubMed
  57. Radiology. 2007 Aug;244(2):599-607 - PubMed
  58. Hepatology. 2009 Feb;49(2):658-64 - PubMed
  59. Hepatology. 2000 Jan;31(1):54-8 - PubMed
  60. Cancer. 1988 Aug 1;62(3):479-83 - PubMed
  61. Hepatology. 2007 Jan;45(1):9-15 - PubMed
  62. Nat Clin Pract Gastroenterol Hepatol. 2009 Mar;6(3):159-69 - PubMed
  63. J Gastroenterol Hepatol. 2006 Sep;21(9):1478-82 - PubMed
  64. Am J Gastroenterol. 2000 Jan;95(1):218-22 - PubMed

Publication Types